🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with semaglutide liver fat quantification? Page 5

Has anyone dealt with semaglutide liver fat quantification?

NeuroNate Wed, Apr 1, 2026 at 3:45 PM 24 replies 886 viewsPage 5 of 5
oliver_london
Member
312
1,345
Aug 2024
London, UK
Apr 6, 2026 at 4:20 AM#21
Dr.PulmRoch said:
Steady state is the thing most people miss.

Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.

That is the short version; the long version is somebody else's post.

Last edited: Apr 6, 2026 at 5:20 AM
1 24Admin
Reply Quote Save Share Report
LondonLisa
Member
912
3,456
Mar 2024
London, UK
Apr 6, 2026 at 1:38 PM#22
Dr.PulmRoch said:
Steady state is the thing most people miss.

Genuinely useful, thank you. I had the facts and not the framework. Printing the relevant bit and taking it with me.

2 0Dr.MetabolicMD, RetaRick_CA
Reply Quote Save Share Report
VanRx_Mike
Member
678
2,890
May 2024
Vancouver, CA
Apr 6, 2026 at 10:56 PM#23

Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

3 1Admin, Dr.Martinez, mike_mod
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
KristenIndy
Member
623
2,678
May 2024
Indianapolis, IN
Apr 7, 2026 at 8:14 AM#24
VanRx_Mike said:
The useful move here is to separate what is established from what is widely repeated.

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

4 2DataDave, Dr.GutHealth, amsterdam_pete and 1 other
Reply Quote Save Share Report
KetoKyle
Member
678
3,456
Jul 2024
Utah
Apr 7, 2026 at 5:31 PM#25
VanRx_Mike said:
The useful move here is to separate what is established from what is widely repeated.

There is a second half to this that has not been said yet. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

5 3JakeBK_lifts, DerekSJ_a1c, paige_pharma and 2 others
Reply Quote Save Share Report
1345

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register